MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Clinical trials for MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS explained in plain language.
Never miss a new study
Get alerted when new MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS trials appear
Sign up with your email to follow new studies for MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New psoriasis drug shows promise in chinese trial
Disease control CompletedThis study tested a drug called bimekizumab in 133 Chinese adults with moderate to severe plaque psoriasis. Participants received either the drug or a placebo for 16 weeks. The main goal was to see if bimekizumab could significantly clear skin compared to placebo. This is a disea…
Matched conditions: MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated May 26, 2026 12:12 UTC
-
New psoriasis drug shows promise in major trial
Disease control CompletedThis study tested a new drug called bimekizumab in 567 adults with moderate to severe plaque psoriasis. The goal was to see if it could clear skin better than a placebo or an existing treatment. Participants received injections and were monitored for improvement in skin redness, …
Matched conditions: MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated May 26, 2026 12:10 UTC
-
New shot shows promise for tough psoriasis cases
Disease control CompletedThis study tested a new medicine called JS005, given as a shot under the skin, for adults with moderate to severe plaque psoriasis. The trial involved 747 people and compared JS005 to a placebo to see if it could clear skin symptoms. The main goals were to measure how many patien…
Matched conditions: MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 12:09 UTC
-
New psoriasis drug shows promise in Head-to-Head trial against stelara
Disease control CompletedThis study tested whether a new drug called Bmab 1200 works as well as the approved drug Stelara for adults with moderate to severe plaque psoriasis. 384 participants received either Bmab 1200 or Stelara, and researchers measured skin clearance using the Psoriasis Area and Severi…
Matched conditions: MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: Biocon Biologics UK Ltd • Aim: Disease control
Last updated May 26, 2026 12:00 UTC
-
New psoriasis drug shows promise in Long-Term safety trial
Disease control CompletedThis study looked at the long-term safety of bimekizumab, a drug for moderate to severe plaque psoriasis, in over 1,300 adults. Participants who had completed earlier studies received the drug for up to several years. The main goal was to track side effects and see how well the b…
Matched conditions: MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New psoriasis drug shows promise in Head-to-Head trial
Disease control CompletedThis study tested a new drug called bimekizumab against an existing drug, secukinumab, in 743 adults with moderate to severe plaque psoriasis. The main goal was to see how many people achieved complete skin clearance after 16 weeks of treatment. Both drugs are biologics that help…
Matched conditions: MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
New psoriasis drug shows promise in major trial
Disease control CompletedThis study tested a drug called bimekizumab against a placebo in 435 adults with moderate to severe plaque psoriasis. The goal was to see if the drug could clear or nearly clear skin patches. Results showed significant improvement in skin symptoms for those taking bimekizumab.
Matched conditions: MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
New hope for kids with psoriasis: Real-World study shows cosentyx works
Disease control CompletedThis study followed 42 children aged 6 to 17 with moderate to severe plaque psoriasis in China who were treated with Cosentyx (secukinumab) for up to 52 weeks. Researchers tracked side effects and how well the drug cleared skin symptoms. The goal was to see if Cosentyx is safe an…
Matched conditions: MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 13, 2026 16:01 UTC